Marseille Immunopole

The French #ImmunologyCluster #CrossInnovation in #ImmunoOncology and #InflammatoryDiseases #Immunotherapy #MonoclonalAntibody #InnateImmunity #Immunoscore...

[Innate Pharma @InnatePharma]

Yesterday, we were pleased to announce the publication of preclinical data with a trispecific NK cell engager in acute myeloid leukemia in @NatureBiotech

Click here 👉 https://t.co/5ecnCmy8CH

@sanofi #InnateImmunity #InnateImmune #Oncology #Cancer #NKcell #CellulesNK #ANKET

[Marseille Immunopole @Immunopole]

Learn more about ImCheck’s partnership with @LLSResearch TAP by attending this live one-hour virtual discussion panel on January 18, 2023, at 18:00 PM CET/12:00 noon ET/9:00 AM PT/6:00 PM CET
Register @ https://t.co/6qpwFe6mE9

[Blood Cancer United Research @bcutd_research]

Our Therapy Acceleration Program #LLSTAP is excited to announce the upcoming panel “European Partners Dream Big, Make Bold Progress” highlighting TAP companies @affimed @FaronPharm @RyvuTx and ImCheck on Wed Jan 18 2023 @ 12 pm ET!
Join us & register @ https://t.co/StKpdItVga

[Fabrice Barlesi @barlesi]

A major step for all the partners of the #PioneerProject with ~50% of pts treated w chemo/IO this study will be able to consolidate our biomarkers panel to predict PFS presented @EsmoIO

[Marseille Immunopole @Immunopole]

The RHU PIONeeR project announces the completion of a major milestone with 450 patients enrolled in the biomarker part of the study, led by @Veracyte, in early 2023.
#oncology #immunotherapy #NSCLC #PD1 #PD1L1 #precisiononcology #France2030
More: https://t.co/BO47jIcRFd
@barlesi

[AP-HM - Hôpitaux Universitaires de Marseille @aphm_actu]

#ÉPIDÉMIES 🦠 Il est plus que jamais important de rappeler la nécessité de respecter les #GestesBarrières.

[Stephen V Liu, MD @StephenVLiu]

Excellent discussion, as usual, from Dr. @peters_solange at the #ASCOPlenarySeries, showing how vast the immunotherapy (and specifically the #TIGIT) landscape has become in a relatively short time. #LCSM

[Fabrice Barlesi @barlesi]

An IA based ML signature based on 15 biomarkers developped on #ThePioneerProject separates adv NSCLC pts with Early progression on chemo-IO with a .84 AUC. An academic effort highlighted by Ignacio Melero @myESMO IO meeting @LGreillier @SBenzekry

[Marseille Immunopole @Immunopole]

Attending #ESMOImmuno22?
Don't miss the presentation on the #PIONeeRproject with @barlesi today at 14:45 "Comprehensive #biomarkers analysis to predict efficacy of #PD1L1 #ICIs in combination with #chemotherapy: a subgroup analysis of the PIONeeR trial"
#NSCLC #precisiononcology

[Innate Pharma @InnatePharma]

Three posters showcasing IPH5201 and IPH5301 will be presented at #ESMOio22.

Learn more: https://t.co/VyOro6IDWI

@myESMO

[Icahn School of Medicine at Mount Sinai @IcahnMountSinai]

Dr. @MiriamMerad, VP of @iuis_online and Director of @SinaiImmunol, invites you to join IUIS 2023 which brings together 5,000+ immunologists to leverage the connectivity between human health and basic immunology – in South Africa, Africa, and globally: https://t.co/BClEx0IxBK

[Marseille Immunopole @Immunopole]

Le #Biocluster en #Immunologie Marseille #Immunopole conforte son leadership avec la nomination de Daniel Olive à la présidence de la @sfiimmunologie. Félicitations Daniel!
https://t.co/0NZXRkkTTC #immunopole

[Marseille Immunopole @Immunopole]

We are glad to share with you the 2 posters on the #PioneerProject presented today at the @sitcancer annual meeting
#SITC2022 #immunotherapy
https://t.co/kkYTdDDz59 #immunopole

[Marseille Immunopole @Immunopole]

Le #Biocluster en #Immunologie Marseille #Immunopole conforte son leadership avec la levée de fonds record d’@ImcheckThx #NextGenerationImmunology https://t.co/6sKxV5IVpI

[Le Monde Sciences @lemonde_science]

ImCheck Therapeutics à l’assaut d’une nouvelle génération d’anticancéreux https://t.co/scLXXz9UqS

[Marseille Immunopole @Immunopole]

Congratulation to our founding member @ImcheckThx for this impressive financing!

[Marseille Immunopole @Immunopole]

Le #RHU #ThePIONeeRProject a désormais sa page Linkedin! Abonnez vous pour ne rater aucune information !
https://t.co/HmgwjET2AC

@barlesi @univamu @aphm_actu @Inserm @CNRS
@AstraZeneca @Veracyte_IO @InnatePharma
@ImcheckThx @CLCCLeonBerard @paoli_calmettes @CHUdeToulouse

[Marseille Immunopole @Immunopole]

D-1 ! Attending #AACR22? Don't miss our poster "Comprehensive #biomarkers analysis to explain resistances to PD1/L1 ICIs:The Precision #ImmunoOncology for advanced #NSCLC (PIONeeR) trial" April 12, 9:00 AM-12:30 PM Section 17
@barlesi from @GustaveRoussy @univamu @aphm_actu